



MEDTECS INTERNATIONAL CORPORATION LIMITED
(Incorporated in Bermuda)

Board Approval for the Company to Apply for Transfer to the Mainboard

The Board of Directors ("**Board**") of Medtecs International Corporation Limited (the "**Company**") wishes to announce that the Board intends to make an application to transfer the Company's listing from the Catalist to the Mainboard of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") (the "**Proposed Transfer**").

The Board believes the Proposed Transfer would better allow the Company to attract institutional investors and reach out to a wider investor base, both within Singapore and overseas. This, coupled with the fact that a listing on the Mainboard would enhance the image of the Company and provide the Company with greater visibility and recognition in the market, is particularly critical in this COVID-19 pandemic situation, where there could be pockets of opportunities that Company would be able to tap on to expand its business operations.

The Company will be submitting an application to the SGX-ST for the Proposed Transfer and will update its shareholders on the outcome of the applications to the SGX-ST in due course.

The Proposed Transfer is subject to, amongst others, the following conditions:

- (a) the in-principle approval of the SGX-ST for the Proposed Transfer being obtained;
- (b) the Company meeting the minimum quantitative requirements set out in Mainboard Rule 210; and
- (c) the approval of the Company's shareholders for the Proposed Transfer being obtained at an extraordinary general meeting to be convened.

Shareholders are advised to exercise caution in trading their shares as there is no certainty or assurance as at the date of this announcement that approval by the SGX-ST for the Proposed Transfer will be obtained, the above conditions will be met, or that the Proposed Transfer will be undertaken at all.

Shareholders are advised to read this announcement and any further announcements by the Company carefully. Shareholders should consult their stock brokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions that they should take.

Submitted by Mr Clement Yang, Executive Chairman, on 16 November 2020 to the SGX-ST.

For further information, please contact:
Citigate Dewe Rogerson Singapore Pte Ltd
Ms Samantha Koh / Mr Justin Teh
Tel: +65 6534 5122
Email: investor.relations@medtecs.com

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd, ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**"). The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the figures used, statements, opinions or other information made or disclosed.*

This announcement has not been examined or approved by the Exchange. The Exchange assumes no

responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Ms Evelyn Wee (Tel no.: +65 6232 0724) and Mr Howard Cheam Heng Haw (Tel no.: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.